Dr Reddy’s Laboratories is navigating a critical transition phase as legacy gains from gRevlimid taper off, even as the company lays the groundwork for its next multi-year growth cycle.
Gujarat Themis Biosyn Limited (GTBL), a niche pharmaceutical manufacturer specializing in fermentation-based intermediates, is entering a decisive phase of strategic evolution. BP Equities Pvt.
Ventura Securities has initiated coverage on Jubilant Pharmova Ltd with a "BUY" recommendation at the current market price of Rs 1,067, assigning a 24-month price target of Rs 1,557, representing a
ICICI Direct has refrained from issuing a traditional recommendation for the Corona Remedies initial public offering, designating it as "UNRATED" in their latest assessment.
Axis Securities Limited has issued a BUY recommendation for Biocon Limited, positioning the pharmaceutical giant as their "Pick of the Week" with a compelling investment thesis.
